- CTVA US : Corteva, a $50 Billion Seed-and-Pesticide Maker, Is Exploring a Breakup -- WSJ
- MC FP /EL FP : The battle for Armani: will his anointed suitors swoop on late designer’s empire? - FT
- Medline IPO : Medline readies IPO in coming months in test of investor appetite, Offering seen as signal of whether large private equity groups can begin exiting largest deals - FT
- NESN SW : Nestlé investors call for chair to step down over executive turmoil - FT
- PFE US :Pfizer Is Growing More Reliant on Vaccines as Controversies Swirl, Vaccines could comprise a quarter of Pfizer’s revenue by 2030 as patents expire on other drugs. - Barron's
- 9992 HK : Pop Mart : Labubu has nothing to fear from Wakuku or Lafufu, Pop Mart’s elflike doll has its rivals but the greatest threat may be the temporary nature of viral toy crazes - FT Lex
- 9992 HK :Pop Mart : Labubu May Have Peaked for Now, but Pop Mart Is Here to Stay, With international expansion at a steady pace and a roster of popular artist IPs beyond Labubu, the Chinese blind box and plush toy maker is looking at $4.18 billion in 2025 revenue with ease. - WWD
- SBRY LN : Sainsbury’s in talks to sell Argos to China’s JD.com - FT
- STAL US : Jeep’s Comeback Plan: First, Bring Back the Cherokee, After sales fell and dealers revolted, the company reverses course and revives the popular model - WSJ
- Pharma Sector : US urged UK to offer better drug pricing deal to pharma companies - FT
- EU Merger Reform : Antitrust chief Teresa Ribera under pressure as EU merger reform drifts, Commission’s executive vice-president has yet to lay out policy vision, creating uncertainty for dealmakers - FT